bluebird bio Flies Forward

Development-stage biotech bluebird bio (NASDAQ:BLUE) released first-quarter earnings without much fanfare given the lack of a product on the market. Fortunately, the biotech is on the cusp of having an approved drug and plans to hold an analyst day this week where investors can get a little more insight into its plans.